| Name | Title | Contact Details |
|---|
Manhattan Research is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
The Hydropothecary is a licensed producer and distributor of medical marijuana under Health Canada`s Access to Cannabis for Medical Purposes Regulations (ACMPR). We are committed to medical excellence and achieve this through our growing techniques, process control, quality assurance testing, robust research and development, and by offering an exceptional customer service experience. We are proud of our company`s remarkable growth thus far and look forward to our continued expansion with the construction of a new greenhouse which will boast an additional 250,000 sq/ft in 2018. We are constantly seeking skilled, energetic and highly focused p-professionals who would like the opportunity to be a part of our team and of an exciting industry that is constantly evolving.
InflaRx (Nasdaq:IFRX) is a clinical-stage biopharmaceutical company focused on applying its proprietary anti-C5a technology to discover and develop first-in-class, potent and specific inhibitors of C5a. Complement C5a is a powerful inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. InflaRx was founded in 2007 and the group has offices and subsidiaries in Jena and Munich, Germany as well as Ann Arbor, Michigan. InflaRx is listed on the Nasdaq Global Select Market in the United States under the trading symbol “IFRX”.
RedPath Integrated Pathology, Inc. is a Pittsburgh-based molecular diagnostics laboratory focused on providing novel solutions for clinicians. RedPath’s patented PathFinderTG® platform produces mutational profiles to help physicians resolve complex diagnostic dilemmas in patients who are at risk of cancer. RedPath performs all clinical testing and R&D in its state-of-the-art, CLIA-certified and CAP-accredited laboratory. The PathFinderTG platform is supported by more than 20 years of scientific and clinical research, and studies using it have been published in more than 200 peer-reviewed journals, including The New England Journal of Medicine. Based on the strong clinical data supporting this platform, RedPath has received positive coverage decisions from Medicare and private payers.
Kleo Pharmaceuticals is advancing the field of immunotherapy by developing small molecules that emulate biologics.